Compare American Superconductor Corporation (AMSC) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Superconductor Corporation vs Bristol-Myers Squibb Co — how do they compare? American Superconductor Corporation trades at $32.59 (market cap $1.56B), while Bristol-Myers Squibb Co trades at $63.73 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 83.3× American Superconductor Corporation's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while American Superconductor Corporation pays none. Which is the better fit depends on your goals.
| AMSC | BMY | |
|---|---|---|
Market Cap | $1.56B | $129.94B |
Sector | Technology | Health |
52-Week High | $66.68 | $65.89 |
52-Week Low | $25.95 | $42.60 |
Enterprise Value | $1.42B | $163.92B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $32.64, up 5.32% in 24 hours, with a bearish technical signal from moving averages. Recent Q1 2026 earnings missed estimates despite record revenue growth, while Q4 2025 and Q1 2026 beat expectations. The company shows strong profitability with a net income margin of 42.56% and ROE of 30.16%, but faces margin pressure and a high EV/EBITDA of 65.73. News highlights record orders and backlog growth amid concerns over valuation and business mix.
Outlook is mixed: bullish fundamentals from earnings beats and order momentum contrast with bearish technicals and valuation risks. Opportunities lie in Grid and Wind segment expansion, but investors face headwinds from margin compression and competitive pressures. Analyst consensus leans buy (53.33%), suggesting cautious optimism for growth execution.
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
